Healthcare Stocks

Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

 Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

HIGHLIGHTS Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals. In July 2021, the company received approval from the US Patent and Trademark Office for the use of SDC-1802 drug molec...

Read More...
4 Aspects That Can Decide The Future Of Vaccines

4 Aspects That Can Decide The Future Of Vaccines

Source: insta_photosy, Shutterstock Summary The future of vaccines will depend on several factors such as efficacy of next-generation vaccines, logistical, and distribution issues, fast-tracking approvals and latest innovations and technology. ...

Read More...
Vaccine stocks in focus as UK rejects EU’s vaccine export ban claims

Vaccine stocks in focus as UK rejects EU’s vaccine export ban claims

Source: PalSand, Shutterstock  Summary The British government denied false EU claims over vaccine nationalism concerns. Pandemic seems to have proved the worth of prominent vaccine stocks – AZN, MRNA, PFE and BNTX.   A di...

Read More...
Why Moderna, Pfizer Et Al Are Poised for Strong Gains in FY 2021

Why Moderna, Pfizer Et Al Are Poised for Strong Gains in FY 2021

Source: LookerStudio, Shutterstock Summary Several pharmaceutical companies, such as Moderna, Pfizer-BioNTech, Astrazeneca, and others are expected to report huge revenues in FY 2021 as vaccination rollouts gain momentum across the world. Tota...

Read More...
3 FTSE 250 healthcare stocks with over 25% return in last one year 

3 FTSE 250 healthcare stocks with over 25% return in last one year 

Source: janews, Shutterstock  Summary Three FTSE 250 index stocks have given over 25 per cent return on investment in the last one year. Dechra Pharmaceuticals gave 25.16 per cent, Genus Plc 54.21 per cent, and PureTech Hea...

Read More...
Will Moderna’s booster shots be effective on South African variant? 

Will Moderna’s booster shots be effective on South African variant? 

Source: joel bubble ben, Shutterstock Summary Moderna said that it has been able to produce booster shots particularly for the South African variant. The shots have been shipped to the National Institutes of Health in ...

Read More...
Avacta (LON: AVCT) Plans Commercial Launch of Lateral Flow Covid-19 Test by Q1

Avacta (LON: AVCT) Plans Commercial Launch of Lateral Flow Covid-19 Test by Q1

Source: Horth Rasur, Shutterstock Summary Avacta Group is all set to launch its rapid lateral flow Covid test by Q1 2021. The rapid antigen test has been created to spot infectious people for quick isolation. The company would now work toward...

Read More...
What are the recent business updates unveiled by LSE listed Clinigen Group?

What are the recent business updates unveiled by LSE listed Clinigen Group?

Source: Shutterstock Summary Clinigen Group PLC had reported an increase of 4% in net organic revenue during H1 FY21 ended 31 December 2020. CLIN had announced an interim dividend of 2.15 pence per share for H1 FY21. Sam Herbert was appointed...

Read More...
Will AstraZeneca meet its EU delivery targets for the second quarter? 

Will AstraZeneca meet its EU delivery targets for the second quarter? 

  AstraZeneca PLC (LON: AZN) has expressed its disability to deliver the agreed doses of the Covid-19 vaccine to the European Union, but promised to increase the productivity to meet the demand of 180 million doses. An EU official&n...

Read More...
How effective is the Pfizer-BioNtech vaccine against the South African coronavirus strain? 

How effective is the Pfizer-BioNtech vaccine against the South African coronavirus strain? 

Summary A lab study has found that Pfizer-BioNtech vaccine could be less impactful on South African strain. The vaccine had two-thirds less neutralising impact on antibodies against the South African strain. Though the companies...

Read More...
How Kanabo will gain from its smashing debut at London Stock Exchange

How Kanabo will gain from its smashing debut at London Stock Exchange

Summary Kanabo came up with an IPO on 16 February which was worth 4.75 pence per share. The shares quadrupled in value at the closing of the first day of trading. Medical marijuana firm Kanabo, also called Nes...

Read More...